Format

Send to:

Choose Destination
See comment in PubMed Commons below
Ophthalmology. 2003 Jul;110(7):1449-53.

Infliximab in the treatment of refractory posterior uveitis.

Author information

  • 1Department of Ophthalmology and Visual Sciences, B Floor, Eye and ENT Block, Queen's Medical Centre, Nottingham NG7 2UH, United Kingdom.

Abstract

PURPOSE:

To determine the efficacy and safety of infliximab in the treatment of refractory posterior uveitis.

DESIGN:

Noncomparative interventional case series.

PARTICIPANTS:

Five patients with posterior uveitis were treated: 3 had Beh├žet's syndrome, and 2 had idiopathic posterior uveitis.

INTERVENTIONS:

Patients with sight-threatening uveitis refractory to other immunosuppressive agents were treated with infliximab.

MAIN OUTCOME MEASURES:

Intraocular inflammation, by using binocular indirect ophthalmoscopy score, retinal vasculitis, and visual acuity. Adverse effects of infliximab were documented.

RESULTS:

Within 2 weeks of the first infusion of infliximab, 4 of 5 patients showed marked improvement in vitreous haze and visual acuity. By the 6-month follow-up, the same four patients had achieved remission of posterior uveitis and had successfully withdrawn all other immunosuppressive therapy. Further infusions of infliximab were required in 3 patients. One patient developed ocular and systemic tuberculosis, which responded to antituberculous treatment.

CONCLUSIONS:

Infliximab is effective in the treatment of sight-threatening refractory posterior uveitis. However, patients should be thoroughly screened for tuberculosis before treatment and followed up closely during and after therapy with infliximab.

Comment in

PMID:
12867408
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk